深奥的测试市场 - 全球产业规模、份额、趋势、机会和预测，按类型、技术、样本、最终用户、地区和竞争细分，2019-2029F

2023 年全球深奥测试市场估值为 249.6 亿美元，预计到 2029 年预测期内将稳定成长，复合年增长率为 6.83%。这些测试更加复杂，需要专门的设备和专业知识，用于诊断罕见疾病或进行超出传统实验室能力的详细分析。深奥测试的例子包括罕见疾病的基因测试、先进的微生物检测、专门的荷尔蒙评估和自体免疫疾病诊断。这些测试透过识别复杂或不常见的病症、指导治疗决策以及有时预测疾病进展，在临床实践中发挥关键作用。在诊断技术的不断进步以及基因组学和分子诊断与常规临床环境的日益融合的推动下，深奥的检测市场将持续成长。对个人化医疗的重视以及对精确疾病诊断和监测的需求将推动该领域的创新和市场扩张。应对严格的监管框架并获得新的深奥测试的批准可能会给行业参与者带来挑战。与深奥测试相关的较高成本可能会限制其采用，特别是在新兴经济体，这些测试可能无法在所有医疗机构中轻鬆获得。儘管存在这些挑战，在技术进步、医疗保健意识不断增强以及全球慢性病负担不断升级的支持下，深奥的检测市场为诊断检测公司提供了大量机会。

市场概况
预测期	2026-2030
2023 年市场规模	249.6亿美元
2029 年市场规模	366.9亿美元
2024-2029 年复合年增长率	6.83%
成长最快的细分市场	下一代定序
最大的市场	北美洲

主要市场驱动因素

慢性病和传染病的增加

技术进步

主要市场挑战

测试中的不一致和诊断错误

费用和报销问题

主要市场趋势

越来越重视个人化医疗

细分市场洞察

类型洞察

技术洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：COVID-19 对全球深奥测验市场的影响

第 5 章：全球 Esoteric 测试市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依类型（免疫学检测、基因检测、传染病、内分泌检测、肿瘤学检测、毒理学检测、神经学检测等）
  • 按技术分类（化学发光免疫分析、酶联免疫吸附分析、即时 PCR、DNA 定序和新一代定序、流式细胞仪、色谱和质谱、其他技术）
  • 依样本（血液、尿液、其他）
  • 按最终用户（独立和参考实验室以及医院实验室）
  • 按地区
  • 按公司划分 (2023)
• 市场地图

第 6 章：亚太地区 Esoteric 测试市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 依技术
  • 依样本
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 7 章：欧洲 Esoteric 测试市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 依技术
  • 依样本
  • 按最终用户
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 8 章：北美 Esoteric 测试市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 依技术
  • 依样本
  • 按最终用户
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 9 章：南美洲 Esoteric 测试市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 依技术
  • 依样本
  • 按最终用户
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲深奥测验市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按类型
  • 依技术
  • 依样本
  • 按最终用户
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋深奥测试市场前景
    • 市场规模及预测
      • 按价值
    • 市占率及预测
      • 按类型
      • 依技术
      • 依样本
      • 按最终用户

第 11 章：市场动态

• 司机
• 挑战

第 12 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 13 章：全球深奥测验市场：SWOT 分析

第 14 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第15章：竞争格局

• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• HU Group Holdings, Inc.
• OPKO Health, Inc.
• Sonic Healthcare Limited
• Myriad Genetics, Inc.
• Fulgent Genetics, Inc.
• Merck KGaA
• Nelson Laboratories, LLC
• ACM Medical Laboratory, Inc.

第 16 章：策略建议

第17章调查会社について・免责事项

Global Esoteric Testing Market was valued at USD 24.96 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.83% through 2029. Esoteric testing refers to specialized medical tests that are not typically conducted in standard clinical laboratories. These tests are more intricate, requiring specialized equipment and expertise, and are utilized for diagnosing rare conditions or conducting detailed analyses beyond conventional laboratory capabilities. Examples of esoteric tests encompass genetic testing for rare disorders, advanced microbiological assays, specialized hormone evaluations, and autoimmune disease diagnostics. These tests play a critical role in clinical practice by identifying complex or uncommon conditions, guiding treatment decisions, and sometimes predicting disease progression. The esoteric testing market is positioned for sustained growth driven by ongoing advancements in diagnostic technologies and the increasing integration of genomics and molecular diagnostics into routine clinical settings. The emphasis on personalized medicine and the demand for precise disease diagnosis and monitoring will fuel innovation and market expansion in this segment. Navigating stringent regulatory frameworks and obtaining approvals for new esoteric tests can present challenges for industry players. The higher costs associated with esoteric testing may limit adoption, particularly in emerging economies where these tests may not be readily accessible in all medical facilities. Despite these challenges, the esoteric testing market offers substantial opportunities for diagnostic testing companies, supported by technological progress, growing healthcare awareness, and the escalating global burden of chronic diseases.

Market Overview
Forecast Period	2026-2030
Market Size 2023	USD 24.96 Billion
Market Size 2029	USD 36.69 Billion
CAGR 2024-2029	6.83%
Fastest Growing Segment	Next-generation Sequencing
Largest Market	North America

Key Market Drivers

Rise in Chronic and Infectious Diseases

Esoteric tests offer greater sensitivity and specificity compared to conventional methods, facilitating early detection of diseases such as cancer, cardiovascular conditions, and infectious illnesses like HIV/AIDS and hepatitis. Detecting diseases early can result in prompt intervention and better patient outcomes. According to the World Health Organization (WHO), noncommunicable diseases (NCDs) are responsible for 41 million deaths annually, comprising 74% of global mortality. Cardiovascular diseases are the leading cause of NCD deaths, claiming 17.9 million lives annually, followed by cancers (9.3 million), chronic respiratory diseases (4.1 million), and diabetes (2.0 million, including diabetes-related kidney disease deaths).

Many chronic and infectious diseases involve complex molecular and genetic factors that influence their progression and response to treatment. Esoteric testing provides detailed genetic and molecular insights, enabling personalized treatment plans tailored to individual patients' biological profiles. For chronic conditions such as diabetes, autoimmune disorders, or neurological diseases, esoteric tests can accurately monitor disease progression, allowing healthcare providers to adjust treatment strategies in real time and optimize patient care. In the realm of infectious diseases, particularly emerging infections or those with unusual presentations, esoteric testing can identify rare pathogens or variants that standard diagnostic tests might miss. The precision of esoteric tests in detecting infectious diseases swiftly and accurately contributes to effective public health strategies, including disease surveillance, outbreak control, and preventive measures.

The increasing prevalence and complexity of chronic and infectious diseases underscore the crucial role of esoteric testing in modern healthcare. Beyond enhancing diagnostic accuracy and patient outcomes, esoteric testing supports advancements in personalized medicine and public health initiatives. As demand for these tests grows, it is expected to drive innovation and investment in diagnostic technologies.

Advancements in Technology

Technological advancements enable the development of new esoteric tests that identify rare diseases, detect genetic mutations, and reveal biomarkers indicating disease risk or progression. These tests fill critical diagnostic gaps and support personalized medicine approaches. For instance, Reese Pharmaceutical launched ColoTest, an OTC at-home immunochemical fecal occult blood test, in 2024. Innovations like next-generation sequencing, high-throughput screening, and advanced imaging technologies enhance the sensitivity, specificity, and speed of esoteric tests, enabling healthcare providers to detect diseases earlier and more accurately. In April 2024, Labcorp LH introduced Labcorp Plasma Detect, the first whole-genome sequencing solution for detecting circulating tumor DNA (ctDNA) in molecular residual disease assessment for early-stage colon cancer. This technology identifies patients at higher risk of recurrence post-surgery or adjuvant chemotherapy using tumor-informed, clinically validated methods. Technologies that miniaturize and automate laboratory processes reduce turnaround times and operational costs associated with esoteric testing, enhancing accessibility across various healthcare settings.

In 2023, Serum Institute of India and Mylab Discovery Solutions launched a point-of-care skin test for latent tuberculosis infections (LTBI) at a significantly lower cost compared to existing tests. In 2024, Vesica Health, Inc. introduced AssureMDx, a noninvasive urine-based DNA test designed to improve the triage of hematuria patients and early detection of bladder cancer. This test helps physicians identify patients at increased risk for bladder cancer, facilitating prompt urological referral when necessary and reducing unnecessary procedures and radiation exposure. Growing access to health information and awareness of advanced diagnostic technologies drive demand for esoteric testing, as patients and healthcare providers seek more personalized and comprehensive diagnostic solutions. Technological advancements continually propel the esoteric testing market by enhancing diagnostic accuracy, expanding test capabilities, improving operational efficiencies, and meeting evolving healthcare needs. These innovations not only foster market growth but also contribute to better patient outcomes and healthcare delivery.

Key Market Challenges

Inconsistencies and Diagnostic Errors in Testing

Errors in test results can lead to incorrect diagnoses, potentially delaying appropriate treatment or prompting unnecessary interventions. This undermines patient confidence in healthcare providers and testing facilities. According to research from Johns Hopkins School of Medicine, nearly 800,000 Americans annually experience death or permanent disability due to diagnostic errors, often stemming from cognitive mistakes made by treating physicians. Esoteric tests, which often involve complex data interpretation due to their high sensitivity and specificity, are particularly susceptible to misinterpretation or variations in interpretation across different laboratories, which can lead to inconsistent diagnoses and treatment decisions.

The National Center for Biotechnology Information (NCBI) reports that as of 2023, the healthcare industry spends an estimated USD 50 billion to USD 60 billion annually on unsuccessful cancer trials, highlighting the critical need for improved target validation and more suitable preclinical models to minimize trial failures. Ensuring stringent quality control and assurance processes is essential to mitigate errors in testing procedures, sample handling, and result reporting. Achieving consistency across diverse laboratories and testing platforms remains an ongoing challenge. Inaccurate diagnoses can result in delayed or ineffective treatments, exacerbating patient outcomes and potentially increasing healthcare costs due to the need for additional testing or corrective treatments. Addressing these challenges demands continual investment in technology, rigorous adherence to quality assurance protocols, adherence to regulatory requirements, and effective communication between healthcare providers and patients regarding the limitations and implications of diagnostic test results.

Cost and Reimbursement Issues

Esoteric tests often encounter unpredictable reimbursement rates and policies from payers, such as insurance companies and government healthcare programs. In contrast to more established diagnostic tests that benefit from standardized reimbursement codes and rates, esoteric tests may face inconsistent or lower reimbursement, impacting both laboratory profitability and patient affordability. Meeting regulatory requirements for billing and reimbursement further burdens laboratories, necessitating investments in systems and personnel to ensure compliance with guidelines established by government agencies like the Centers for Medicare & Medicaid Services (CMS) in the United States. The high out-of-pocket costs associated with esoteric tests can deter patient access, particularly when insurance coverage is restricted or denied. This financial barrier potentially delays patients from obtaining timely diagnostic information and appropriate medical treatment. Moreover, fierce competition within the esoteric testing market often results in pricing pressures, compelling laboratories to reduce prices to maintain competitiveness. This, in turn, can strain profitability and long-term financial stability.

Key Market Trends

Growing emphasis on Personalized Medicine

Esoteric tests are pivotal in providing precise diagnostic insights based on a patient's unique genetic and molecular profile. These tests can identify specific genetic mutations, biomarkers, or molecular signatures that influence disease susceptibility, progression, and treatment response. Advances in genomic sequencing, bioinformatics, and data analytics are driving the integration of complex data sets to support personalized medicine initiatives. Esoteric testing laboratories are leveraging these technologies to analyze large volumes of genetic and molecular data efficiently and accurately. In July 2024, Spotlight Medical SAS raised USD 6.7 million in seed funding to launch its first artificial intelligence-powered cancer test, aiming to transform cancer treatment. The emerging field of liquid biopsy utilizing cell-free DNA (cfDNA) and circulating tumor cells (CTCs) has opened new avenues for cancer diagnostics with important clinical opportunities for personalized medicine in oncology.

Esoteric tests enable predictive testing to assess an individual's risk of developing certain diseases or conditions based on genetic predisposition or biomarker presence. Prognostic testing helps predict disease progression and outcomes, guiding personalized treatment plans. In 2024, a team of University of Michigan researchers developed a multimodal AI model to predict treatment outcomes of tuberculosis (TB) patients. Their analysis of worldwide patient data can lead to the personalization of TB treatment.

Several organizations, authorities, and governments have focused their attention on personalized medicine. The new European Partnership for Personalised Medicine (EP PerMed), launched in October 2023, aims to boost research in precision medicine across the European Research Area. With 49 partners involved, EP PerMed promotes all areas and disciplines of precision medicine, facilitates innovation and transfer, and encourages its integration into health systems to drive continuous improvement. Personalized medicine shifts the focus from a one-size-fits-all approach to healthcare to one that prioritizes individual patient needs and characteristics. Esoteric testing supports this patient-centric approach by providing clinicians with actionable insights that optimize treatment decisions and improve patient outcomes. The growing emphasis on personalized medicine is driving demand for sophisticated esoteric testing solutions that can deliver precise, actionable insights tailored to individual patient characteristics.

Segmental Insights

Type Insights

Based on Type, the Oncology Testing emerged as the dominating segment in the global market for Esoteric Testing in 2023. Cancer remains a leading cause of illness and death worldwide. The increasing incidence of various cancers, combined with heightened awareness and screening efforts, fuels the demand for oncology testing. According to the World Health Organization (WHO), the projected rise to over 35 million new cancer cases by 2050 represents a 77% increase from the estimated 20 million cases in 2022. This escalating global cancer burden reflects factors such as population aging, growth, and changes in exposure to risk factors linked to socioeconomic development. Advancements in genomic sequencing, molecular diagnostics, and bioinformatics have significantly bolstered the precision and sensitivity of oncology tests. Oncology testing yields actionable insights that enable clinicians to optimize patient care through early detection, accurate diagnosis, prognosis assessment, and ongoing monitoring of cancer progression. This diagnostic information plays a pivotal role in enhancing patient outcomes and improving quality of life. Significant investments in research and development within the oncology field drive continuous innovation in diagnostic technologies and the discovery of novel biomarkers. This ongoing research effort expands the capabilities and applications of oncology testing, further advancing its role in personalized medicine and comprehensive cancer care.

Technology Insights

Based on Technology Type, Next-generation Sequencing emerged as the fastest growing segment in the global market for Esoteric Testing during the forecast period. NGS technology allows for simultaneous sequencing of millions of DNA or RNA strands, providing unparalleled depth and accuracy in genetic analysis. This capability enables the detection of subtle genetic variations, mutations, and disease-associated biomarkers that may be overlooked by traditional methods. Continuous improvements in NGS platforms, bioinformatics tools, and data analysis algorithms have significantly enhanced its efficiency, throughput, and cost-effectiveness. These advancements have reduced barriers to adoption and expanded the scope of genomic research and clinical diagnostics. In 2023, Aventa Genomics introduced Aventa FusionPlus, an NGS test designed to detect gene fusions, translocations, and rearrangements in solid tumor tissue samples preserved in formalin-fixed, paraffin-embedded format. NGS technology finds versatile applications across diverse medical fields, including oncology, infectious diseases, genetic disorders, pharmacogenomics, and prenatal screening. In 2024, Twist Bioscience Corporation launched Twist Precision Dx NGS products compliant with European Union in vitro diagnostic regulations (IVDR). The increasing demand for personalized medicine and the necessity for precise diagnostic tools have driven the rapid expansion of NGS technologies. Healthcare providers and researchers are increasingly seeking robust genomic solutions capable of providing actionable insights to enhance patient outcomes. Ongoing research collaborations and initiatives are fostering innovation in NGS, leading to advancements in sequencing accuracy, scalability, and the development of novel applications. These innovations are further accelerating the market growth of NGS technologies.

Regional Insights

Based on Region, North America emerged as the dominant region in the Global Esoteric Testing Market in 2023. This stems from its advanced healthcare infrastructure, robust research capabilities, supportive regulatory environment, high cancer incidence rates, substantial healthcare expenditures, clinical expertise, and strong patient demand. According to the National Cancer Institute (NCI), it is projected that in 2024, approximately 2,001,140 new cancer cases will be diagnosed in the United States, with an estimated 611,720 deaths from the disease. Among men, prostate, lung, and colorectal cancers are anticipated to comprise 48% of new diagnoses, while breast, lung, and colorectal cancers are expected to account for 51% of new diagnoses among women. In 2020, expenditures for cancer care in the United States alone totaled $208.9 billion, with costs expected to rise as the population ages and cancer incidence increases.

North America's significant healthcare spending facilitates substantial investments in innovative cancer treatments, including advanced technologies like hyperthermia devices. Stringent regulatory frameworks, particularly in the United States, ensure the safety and effectiveness of medical devices and treatments, including hyperthermia systems. Patients in North America are well-informed about various cancer treatment options and actively seek advanced therapies that promise improved outcomes and enhanced quality of life. This informed patient base contributes to the region's high demand for hyperthermia treatments. The United States and Israel will receive $8.4 million in funding from the Israel-US Binational Industrial Research and Development (BIRD) Foundation for nine projects. Among these projects, New Phase and Ultraflex Power Technologies will collaborate on developing an advanced RF (radio frequency) machine. This machine aims to activate cancer treatment nanoparticles for the treatment of metastatic solid tumors through electromagnetic hyperthermia in stage 4 patients. Substantial investments in research institutions, universities, and healthcare centers contribute to the ongoing progress in hyperthermia technology and treatment protocols.

Key Market Players

Quest Diagnostics Incorporated

Laboratory Corporation of America Holdings

H.U. Group Holdings, Inc.

OPKO Health, Inc.

Sonic Healthcare Limited

Myriad Genetics, Inc.

Fulgent Genetics, Inc.

Merck KGaA

Nelson Laboratories, LLC

ACM Medical Laboratory, Inc.

Report Scope:

In this report, the Global Esoteric Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Esoteric Testing Market, By Type:

Immunology Testing Genetic Testing Infectious Diseases Endocrinology test Oncology test Toxicology Testing Neurology Testing Others

Esoteric Testing Market, By Technology:

Chemiluminescence Immunoassay Enzyme-linked Immunosorbent Assay Real-time PCR DNA Sequencing & Next-generation Sequencing Flow Cytometry Chromatography & Mass Spectrometry Other Technologies

** Esoteric Testing Market, By Specimen:

Blood Urine Others

Esoteric Testing Market, By End User:

Independent and Reference Laboratories Hospital Laboratories

Esoteric Testing Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Esoteric Testing Market.

Available Customizations:

Global Esoteric Testing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Impact of COVID-19 on Global Esoteric Testing Market

5. Global Esoteric Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Immunology Testing, Genetic Testing, Infectious Diseases, Endocrinology test, Oncology test, Toxicology Testing, Neurology Testing, and Others)
  • 5.2.2. By Technology (Chemiluminescence Immunoassay, Enzyme-linked Immunosorbent Assay, Real-time PCR, DNA Sequencing & Next-generation Sequencing, Flow Cytometry, Chromatography & Mass Spectrometry, Other Technologies)
  • 5.2.3. By Specimen (Blood, Urine, Others)
  • 5.2.4. By End User (Independent and Reference Laboratories, and Hospital Laboratories)
  • 5.2.5. By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map

6. Asia Pacific Esoteric Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Technology
  • 6.2.3. By Specimen
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Esoteric Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Specimen
      • 6.3.1.2.4. By End User
  • 6.3.2. India Esoteric Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Specimen
      • 6.3.2.2.4. By End User
  • 6.3.3. Australia Esoteric Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Specimen
      • 6.3.3.2.4. By End User
  • 6.3.4. Japan Esoteric Testing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Technology
      • 6.3.4.2.3. By Specimen
      • 6.3.4.2.4. By End User
  • 6.3.5. South Korea Esoteric Testing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Technology
      • 6.3.5.2.3. By Specimen
      • 6.3.5.2.4. By End User

7. Europe Esoteric Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Technology
  • 7.2.3. By Specimen
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Esoteric Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Specimen
      • 7.3.1.2.4. By End User
  • 7.3.2. Germany Esoteric Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Specimen
      • 7.3.2.2.4. By End User
  • 7.3.3. Spain Esoteric Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Specimen
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Esoteric Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Specimen
      • 7.3.4.2.4. By End User
  • 7.3.5. United Kingdom Esoteric Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Specimen
      • 7.3.5.2.4. By End User

8. North America Esoteric Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Technology
  • 8.2.3. By Specimen
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Esoteric Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Specimen
      • 8.3.1.2.4. By End User
  • 8.3.2. Mexico Esoteric Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Specimen
      • 8.3.2.2.4. By End User
  • 8.3.3. Canada Esoteric Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Specimen
      • 8.3.3.2.4. By End User

9. South America Esoteric Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Technology
  • 9.2.3. By Specimen
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Esoteric Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Specimen
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Esoteric Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Specimen
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Esoteric Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Specimen
      • 9.3.3.2.4. By End User

10. Middle East and Africa Esoteric Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Technology
  • 10.2.3. By Specimen
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Esoteric Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Specimen
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Esoteric Testing Market Outlook
    • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Specimen
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Esoteric Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Specimen
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Esoteric Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Quest Diagnostics Incorporated
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
• 15.2. Laboratory Corporation of America Holdings
• 15.3. H.U. Group Holdings, Inc.
• 15.4. OPKO Health, Inc.
• 15.5. Sonic Healthcare Limited
• 15.6. Myriad Genetics, Inc.
• 15.7. Fulgent Genetics, Inc.
• 15.8. Merck KGaA
• 15.9. Nelson Laboratories, LLC
• 15.10. ACM Medical Laboratory, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer